商业保险与联邦医疗保险下结直肠癌筛查的效果与成本效果对比
研究采用经验证的马尔可夫队列模拟,比较商业保险(50-64岁)与联邦医疗保险(65-80岁)下结直肠癌筛查的成本效果。结果显示,若商业支付方仅考虑50-64岁时间跨度,结肠镜检查成本较高(每获得一个质量调整生命年超过185,000美元),而粪便潜血试验和粪便免疫化学检测具有成本效果(每获得一个质量调整生命年低于61,000美元)。结论认为,即使考虑商业保险较高支付费率,终生筛查仍具高度成本效果,但大部分临床和经济收益在65岁及以上由联邦医疗保险获得。
要点
- 商业支付方仅考虑50-64岁时,结肠镜每QALY成本超过185,000美元,FOBT和FIT低于61,000美元。
- 联邦医疗保险在65岁及以上获得筛查的主要临床获益和成本节约。
- 已筛查者继续FOBT和FIT可节约成本,继续结肠镜每QALY成本低于30,000美元。
核心结论
- 模型提示,即使考虑商业支付方较联邦医疗保险更高的支付费率,结直肠癌筛查终生仍具高度成本效果。
- 若商业支付方仅考虑50-64岁时间跨度,筛查可能显得相对昂贵,但预计可在65岁及以上由联邦医疗保险获得大部分临床和经济收益。
研究设计与样本
- 研究使用经验证的马尔可夫队列模拟,针对美国平均风险人群,从医疗保健部门视角分析结直肠癌筛查。
- 商业保险下分析50-64岁筛查,联邦医疗保险下分析65-80岁筛查,模型结局包括贴现的质量调整生命年和每人成本及增量成本/QALY。
主要发现
- 对于65岁以下人群,采用商业支付费率而非联邦医疗保险费率时,终生每人成本高20-44%。
- 50-64岁筛查的大部分实质性临床获益在65岁及以上实现。
- 商业支付方时间跨度为50-64岁时,FOBT和FIT具有成本效果(每QALY成本低于61,000美元),结肠镜成本较高(每QALY成本超过185,000美元)。
- 联邦医疗保险从65岁以下已进行的筛查中获得实质性临床获益和成本节约,即使未继续筛查。
- 在已筛查者中,联邦医疗保险下继续FOBT和FIT可节约成本,继续结肠镜具高度成本效果(每QALY成本低于30,000美元);在未筛查者中启动任何筛查均高度有效且节约成本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Most cost-effectiveness analyses of colorectal cancer (CRC) screening assume Medicare payment rates and a lifetime horizon. Our aims were to examine the implications of differential payment levels and time horizons for commercial insurers vs. Medicare on the cost-effectiveness of CRC screening. METHODS: We used our validated Markov cohort simulation of CRC screening in the average risk US population to examine CRC screening at ages 50-64 under commercial insurance, and at ages 65-80 under Medicare, using a health-care sector perspective. Model outcomes included discounted quality-adjusted life-years (QALYs) and costs per person, and incremental cost/QALY gained. RESULTS: Lifetime costs/person were 20-44% higher when assuming commercial payment rates rather than Medicare rates for people under 65. Most of the substantial clinical benefit of screening at ages 50-64 was realized at ages ≥65. For commercial payers with a time horizon of ages 50-64, fecal occult blood testing (FOBT) and fecal immunochemical testing (FIT) were cost-effective (<$61,000/QALY gained), but colonoscopy was costly (>$185,000/QALY gained). Medicare experienced substantial clinical benefits and cost-savings from screening done at ages <65, even if screening was not continued. Among those previously screened, continuing FOBT and FIT under Medicare was cost-saving and continuing colonoscopy was highly cost-effective (<$30,000/QALY gained), and initiating any screening in those previously unscreened was highly effective and cost-saving. CONCLUSIONS: Modeling suggests that CRC screening is highly cost-effective over a lifetime even when considering higher payment rates by commercial payers vs. Medicare. Screening may appear relatively costly for commercial payers if only a time horizon of ages 50-64 is considered, but it is predicted to yield substantial clinical and economic benefits that accrue primarily at ages ≥65 under Medicare.
引用
- Ladabaum U, Mannalithara A, Brill JV, et al. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. Am J Gastroenterol. 2018. PMID: 29904156. doi:10.1038/s41395-018-0106-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。